The late follow-up endoscopy as bleeding prevention after the gastric endoscopic submucosal dissection in the patient with thienopyridine derivative or low-dose aspirin and warfarin combination

The late follow-up endoscopy as bleeding prevention after the gastric endoscopic submucosal dissection in the patient with thienopyridine derivative or low-dose aspirin and warfarin combination - ESD follow-up endoscopy Hokuriku Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016475

Enrollment

150

Registered

2015-02-08

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenoma or early gastric cancer(cStage IA)

Interventions

late follow-up endoscopy group (A group) non-follow-up endoscopy group (B group)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. treatment before endoscopic diagnosis, it has been diagnosed with stomach adenomas or early gastric cancer of clinical stage IA. 2. single multiple is not limited, but the endoscopic treatment plan lesions are only one lesion. 3. thienopyridine derivatives those who are taking, or low-dose aspirin and warfarin in combination with those who are taking 4. Gender: unquestioned, Age: persons age at the time of consent acquisition is greater than or equal to 20 years of age 5. PS ECOG is either 0, 1, 2. 6. all satisfy the following condition. hemoglobin 9g/dl~ platelet count 100,000 / mm3~ AST/ALT ~100 serum creatinine ~2.0mg / dl PT-INR% 80%~

Exclusion criteria

Exclusion criteria: 1. there is a registration history in this study. 2. including for other carcinomas, there is a history of radiation therapy to the upper abdomen. 3. esophageal lesions, there is a plan of endoscopic therapy at the same time against duodenal lesions. 4. within registration before the 28th there is the endoscopic treatment history with respect to the upper gastrointestinal tract lesions. 5. within 28 days after treatment is scheduled to undergo an endoscopic examination or treatment with respect to the upper gastrointestinal tract. 6. continuous systemic administration of antiplatelet or anticoagulant agents other than low-dose aspirin and warfarin or thienopyridine, or steroids. 7. temporary interruption of non-steroidal anti-inflammatory drugs is impossible from ESD treatment 7 days up to 28 days after ESD treatment. 8. childbearing potential during pregnancy or lactating women. 9. have a psychosis or mental symptoms. 10. activity of bacterial and fungal infections. 11. merged the poor control of hypertension. 12. merged the respiratory disease requiring sustained oxygen administration. 13. principal investigator or researcher has determined to be inappropriate.

Design outcomes

Primary

Measure	Time frame
The difference in the incidence of bleeding rates after ESD between late endoscopy group and no late endoscopy group	—

Countries

Japan

Contacts

Public ContactTomoyuki Hayashi

Kanazawa University Hospital Department of gastroenterology

hayasix0917@gmail.com076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026